Relapsing-remitting Multiple Sclerosis
📧 Sign up to get email alerts when something new happens for Relapsing-remitting Multiple Sclerosis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2020-01-13Clinical Trial Update: Plegridy Satisfaction Study in Participants [Phase 4]
Phase 4 trial update for Plegridy in participants with relapsing-remitting multiple sclerosis has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2020-01-13Clinical Trial Update: Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting Multiple Sclerosis [Phase 2]
Phase 2 study assessing safety, tolerability, efficacy, and optimal dosing of BAF312 in relapsing-remitting multiple sclerosis has completed…
-
FDA approval · 2020-01-10FDA Approved: OCREVUS — Supplemental Application (Genentech, Inc.)
FDA approved a supplemental application for OCREVUS (ocrelizumab) submitted by Genentech, Inc.
-
CLINICAL_TRIALS trial_result · 2019-12-04Clinical Trial Update: Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019 [Phase 3]
Long-term extension study in multiple sclerosis participants completed following a prior trial; terminated with results posted in 2019.
-
CLINICAL_TRIALS trial_result · 2019-11-22Clinical Trial Update: Extension Study of BG00012 in Pediatric Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) [Phase 3]
Phase 3 extension study in pediatric relapsing-remitting multiple sclerosis completed; results posted in 2019.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2019-11-06Clinical Trial Update: Estriol Treatment in Multiple Sclerosis (MS): Effect on Cognition [Phase 2]
Phase 2 trial evaluating estriol treatment for cognitive effects in multiple sclerosis patients.
-
CLINICAL_TRIALS trial_result · 2019-10-31Clinical Trial Update: Fingolimod Versus Dimethyl-fumarate in Multiple Sclerosis [Phase 4]
A Phase 4 trial comparing fingolimod to dimethyl fumarate in relapsing-remitting multiple sclerosis was terminated.
-
CLINICAL_TRIALS trial_result · 2019-10-30Clinical Trial Update: A Study to Assess the Effect of a Single Infusion of VAY736 on Disease Activity in Patients With Relapsing-remitting Multiple Sclerosis [Phase 2]
Phase 2 trial evaluating a single infusion of VAY736 in relapsing-remitting multiple sclerosis; study terminated with posted results.
-
CLINICAL_TRIALS trial_result · 2019-09-30Clinical Trial Update: Fingolimod Effect on Cytokine and Chemokine Levels [Phase 4]
Phase 4 clinical trial evaluating fingolimod effects on cytokine and chemokine levels in relapsing remitting multiple sclerosis completed wi…
-
CLINICAL_TRIALS trial_result · 2019-09-24Clinical Trial Update: Efficacy and Safety of Daclizumab in Participants With RRMS Switching From Natalizumab [Phase 3]
Phase 3 trial evaluating efficacy and safety of daclizumab in RRMS patients switching from natalizumab; study terminated with posted results…
-
CLINICAL_TRIALS trial_result · 2019-07-18Clinical Trial Update: Glatiramer Acetate (Copaxone®) Study to Follow Participants From the First Original Study for Safety and Effectiveness [Phase 4]
Phase 4 trial update following participants from the original study to assess safety and effectiveness of glatiramer acetate (Copaxone) in r…
-
CLINICAL_TRIALS trial_result · 2019-06-27Clinical Trial Update: Effect of BG00012 on Lymphocyte Subsets and Immunoglobulins in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS). [Phase 3]
Phase 3 trial update assessing BG00012 effects on lymphocyte subsets and immunoglobulins in relapsing-remitting multiple sclerosis; study co…
-
CLINICAL_TRIALS trial_result · 2019-05-28Clinical Trial Update: MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone [Phase 3]
Phase 3 trial comparing two doses of fingolimod to Copaxone in relapsing-remitting multiple sclerosis was terminated with posted results.
-
CLINICAL_TRIALS trial_result · 2019-03-27Clinical Trial Update: An Extension Study of LAQ/5062 Exploring the Long Term Safety, Tolerability and Clinical Effect Parameters During the Disease [Phase 2]
Phase 2 extension study evaluating long-term safety and tolerability of LAQ/5062 in relapsing remitting multiple sclerosis was terminated wi…
-
CLINICAL_TRIALS trial_result · 2019-02-20Clinical Trial Update: Mitochondrial Dysfunction and Disease Progression
A completed clinical trial (NCT02549703) examining the role of mitochondrial dysfunction in disease progression across multiple sclerosis fo…
-
CLINICAL_TRIALS trial_result · 2019-02-12Clinical Trial Update: Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JC Virus Antibody Negative Participants
An observational study evaluating natalizumab (Tysabri) in early relapsing-remitting multiple sclerosis patients who are anti-JC virus antib…
-
CLINICAL_TRIALS trial_result · 2019-02-08Clinical Trial Update: Follow up Study of Patients on Fingolimod Who Were Enrolled in the Original Biobank Study (CFTY720DDE01) [Phase 4]
Phase 4 follow-up study of fingolimod in relapsing-remitting multiple sclerosis; results from the original biobank study were posted.
-
CLINICAL_TRIALS trial_result · 2019-02-06Clinical Trial Update: Helminth-induced Immunomodulation Therapy (HINT) in Relapsing-remitting Multiple Sclerosis [Phase 1]
Phase 1 trial update reporting completion of helminth-induced immunomodulation therapy (HINT) in Relapsing-remitting multiple sclerosis.
-
CLINICAL_TRIALS trial_result · 2019-01-25Clinical Trial Update: Efficacy of Fingolimod in de Novo Patients Versus Fingolimod in Patients Previously Treated With a First Line Disease Modifying Therapy [Phase 4]
Phase 4 clinical trial update comparing Fingolimod efficacy in de novo Relapsing-Remitting Multiple Sclerosis patients versus those previous…
-
CLINICAL_TRIALS trial_result · 2018-12-07Clinical Trial Update: Alemtuzumab on Surrogate Markers of Disease Activity and Repair Using Advanced MRI Measures in Subjects With Relapsing Remitting Multiple Sclerosis [Phase 4]
Phase 4 clinical trial evaluating alemtuzumab on MRI surrogate markers of disease activity and repair in relapsing remitting multiple sclero…
-
CLINICAL_TRIALS trial_result · 2018-11-21Clinical Trial Update: TMP001 in Relapsing-remitting Multiple Sclerosis [Phase 2]
Phase 2 clinical trial of TMP001 in relapsing-remitting multiple sclerosis has been completed.
-
CLINICAL_TRIALS trial_result · 2018-11-20Clinical Trial Update: An Efficacy and Safety Study of BG00012 (Dimethyl Fumarate) in Asian Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) [Phase 3]
Phase 3 trial update of BG00012 (Dimethyl Fumarate) in Asian subjects with relapsing-remitting multiple sclerosis (RRMS) has completed.
-
CLINICAL_TRIALS trial_result · 2018-11-15Clinical Trial Update: A Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) [Phase 2]
Phase 2 clinical trial update for relapsing-remitting multiple sclerosis completed with results posted.
-
CLINICAL_TRIALS trial_result · 2018-11-09Clinical Trial Update: Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) (BIIB019) in Participants Who Have Completed Study 205MS202 (NCT00870740) to Treat Relapsing Remitting Multiple Sclerosis [Phase 2]
A Phase 2 extension study evaluating safety and efficacy of daclizumab high yield process (BIIB019) in participants with relapsing-remitting…
-
CLINICAL_TRIALS trial_result · 2018-10-16Clinical Trial Update: Advanced MRI Measures of Repair in Alemtuzumab Treated Patients [Phase 3]
Phase 3 trial update reporting advanced MRI measures of repair in alemtuzumab-treated patients with relapsing-remitting multiple sclerosis.